secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2026-03-20T23:59:59+00:00
Accession:  0001437749-26-009253
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics establishes $750M term loan facility due 2031, repays prior term loans
--------------------------------------------------------------------------------

- Borrowed $750M on March 18, 2026 under new term loan; proceeds used to fully repay initial term loans.
- Loan matures March 18, 2031; interest rate is SOFR + margin starting at 4.75% (or base rate + 3.75%).
- Quarterly amortization payments of $37.5M begin Q1 2030; can be deferred if leverage ratio met.
- Also established uncommitted additional facility of up to $250M.
- Loan secured by substantially all assets of borrower and guarantors; includes customary covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774926009253/0001437749-26-009253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774926009253/tgtx20260319_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-009253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer